文献速递中医内科中药与中成药合理使用中医康复

扶正化瘀片治疗新冠后肺纤维化:多中心随机双盲安慰剂对照试验

Fuzheng Huayu tablets for treating pulmonary fibrosis in post-COVID-19 patients: a multicenter, randomized, double-blind, placebo-controlled trial.
PubMed 文献 · Front Pharmacol · 2025-03-11

本研究为多中心随机双盲安慰剂对照试验,纳入142例新冠出院恢复期肺纤维化患者,评估扶正化瘀片联合维生素C及呼吸功能康复治疗24周的疗效与安全性。结果显示扶正化瘀片组肺纤维化消退率71.2%高于安慰剂组49.2%(p=0.01),肺炎症消退率83.8%高于68.8%(p=0.04),且未报告药物相关不良事件。

要点

  • 扶正化瘀片可提高新冠后肺纤维化消退率,且安全性良好。
  • 第8周FEV1/FVC在扶正化瘀片组高于安慰剂组。
  • 第4周6分钟步行距离增加扶正化瘀片组优于安慰剂组。

核心结论

  • 扶正化瘀片可减轻新冠后肺纤维化,且安全性良好。

研究设计与样本

  • 多中心、随机、双盲、安慰剂对照临床试验,纳入142例新冠出院恢复期肺纤维化患者,随机分为扶正化瘀片组(n=72)和安慰剂组(n=70),治疗24周。

主要发现

  • 第24周肺纤维化消退率扶正化瘀片组71.2%,安慰剂组49.2%(p=0.01)。
  • 第8周FEV1/FVC扶正化瘀片组(87.7±7.2)%高于安慰剂组(82.7±6.9)%(p=0.018)。
  • 第24周肺炎症消退率扶正化瘀片组83.8%,安慰剂组68.8%(p=0.04)。
  • 第4周6分钟步行距离增加扶正化瘀片组(41.4±64.1)m大于安慰剂组(21.8±50.3)m(p=0.05)。
  • 临床症状改善率、生活质量-BREF、PHQ-9、GAD-7评分组间差异无统计学意义(p>0.05)。

关键数值与推荐

  • 主要结局为第24周高分辨率CT评分评估的肺纤维化消退率和肺功能改善(FVC、FEV1、FEV1/FVC)。
  • 次要结局包括6分钟步行距离、肺炎症改善、临床症状和生活质量。
  • 扶正化瘀片组未报告药物相关不良事件。

临床怎么用

  • 对于新冠后肺纤维化患者,可考虑在维生素C和呼吸功能康复基础上加用扶正化瘀片。
  • 治疗期间需监测肺纤维化影像学和肺功能变化。

局限性

  • 肺功能数据有限(原文Limited spirometry data)。
  • 临床症状和生活质量等次要结局未见显著改善。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Effective therapies for pulmonary fibrosis caused by coronavirus disease (COVID-19) and other etiologies are lacking. Our previous studies demonstrated that Fuzheng Huayu tablet (FZHY), a traditional Chinese medicine known for its anti-liver fibrotic properties, can improve lung function in patients with chronic obstructive pulmonary disease and attenuate bleomycin-induced pulmonary fibrosis in rats. PURPOSE: This study aimed to evaluate the efficacy and safety of FZHY in post-COVID-19 pulmonary fibrosis. METHODS: A multi-center, randomized, double-blind, placebo-controlled clinical trial was conducted to evaluate the efficacy of a 24-week treatment with FZHY, combined with vitamin C and respiratory function rehabilitation, for treating pulmonary fibrosis in discharged convalescent COVID-19 patients. The primary outcome was the regression rate of pulmonary fibrosis assessed by the high-resolution computed tomography scores and lung function improvement (forced vital capacity [FVC], forced expiratory volume in one second [FEV1], and FEV1/FVC) after 24 weeks. Secondary outcomes included the 6-min walk distance, improvement in pulmonary inflammation, clinical symptoms, and quality of life. RESULTS: This study included 142 patients, who were randomized to the FZHY (n = 72) and placebo groups (n = 70). By week 24, the regression rates of pulmonary fibrosis in the FZHY and placebo groups were 71.2% and 49.2%, respectively (p = 0.01). Limited spirometry data revealed higher FEV1/FVC in the FZHY group than in the placebo group at week 8 ([87.7 ± 7.2] % vs. [82.7 ± 6.9] %; p = 0.018). The regression rates in pulmonary inflammation in the FZHY and placebo groups were 83.8% and 68.8%, respectively (p = 0.04). At week 4, the increase in 6-min walking distance was greater in the FZHY group than in the placebo group ([41.4 ± 64.1] m vs. [21.8 ± 50.3] m; p = 0.05). However, no significant differences were observed between the groups in the improvement rate of clinical symptoms, quality of life-BREF, patient health questionnaire-9, or generalized anxiety disorder-7 scores (p > 0.05). No drug-related adverse events were reported in the FZHY group. CONCLUSION: FZHY attenuates post-COVID-19 pulmonary fibrosis, with good safety profiles. CLINICAL TRIAL REGISTRATION: https://clinicaltrials.gov/study/NCT04279197, identifier NCT04279197.

来源:Front Pharmacol,查看原文。版权归原作者所有。

引用

  1. Jing F, Wang W, Ke J, et al. Fuzheng Huayu tablets for treating pulmonary fibrosis in post-COVID-19 patients: a multicenter, randomized, double-blind, placebo-controlled trial. Front Pharmacol. 2025. PMID: 40135237. doi:10.3389/fphar.2025.1508276

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。